Sirona Biochem Launches Anti-aging Preclinical Studies
(firmenpresse) - Sirona Biochem Launches Anti-aging Preclinical Studies
Vancouver, British Columbia - September XX, 2014 - Sirona Biochem Corp. (TSX-V: SBM, FSE: ZSB) launches the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem's subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys.
Biogalenys has been chosen to work with the team of scientists at TFChem to develop the studies on the anti-aging technology. The research will provide preclinical data supporting multiple targeted applications using novel in vitro tests with varying stress conditions and cell types. The purpose is to both validate the compounds, and to satisfy the standard cohort of cosmetic safety studies. The data will then be used to determine the optimal commercial applications and joint venture partners.
We are excited to be launching this next phase of development with Biogalenys, said Dr. Howard Verrico, CEO of Sirona Biochem. Our two companies previously worked together successfully on the skin lightening technology and have maintained an excellent relationship of shared knowledge. The research on these anti-aging compounds is exciting from both scientific discovery and commercial opportunity prospectus.
Industry analysts predict that the anti-aging marketplace will reach nearly $285 Billion USD by the year 2018.
http://www.irw-press.at/prcom/images/messages/2014/10689/Glyco Test Initiation September 2014 V4_prcom.001.png
http://www.irw-press.at/prcom/images/messages/2014/10689/Glyco Test Initiation September 2014 V4_prcom.002.jpeg
About Biogalenys
Biogalenys is a French laboratory (CRO) specialized in studies of transmembrane passage across several models of epithelia. Biogalenys provides, tests according to GLP or not, for active ingredients and chemical compounds and biological assays to serve the pharmaceutical and cosmetic industries. The laboratory designs the studies, conduct assays, completes data interpretation and classifies the absorption potential of drug and compounds, using different models for in-vitro, in-vivo and ex-vivo assays. Biogalenys is involved in several projects (approved by Cosmetic Valley) in research in cosmetic using efficient test with culture cells models. For more information please visit: http://www.biogalenys.com
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sironas compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sironas laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton, CFOSirona Biochem Corp. Phone: 1.604.282.6064Email: chopton(at)sironabiochem.com
Sirona Biochem Corp.
605-889 West Pender Street,
Vancouver, BC, Kanada, V6C 3B2
T 604.641.4466
F 604.608.5471
T 1.888.SIRONA1 (7476621) - gebührenfrei
www.sironabiochem.com
TSX-V: SBM
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochems forward-looking statements due to the risks and uncertainties inherent in Sirona Biochems business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Leseranfragen:
Sirona Biochem ist ein Unternehmen mit eigens entwickelter chemischer Verfahrenstechnik, das sich auf die Forschung und Entdeckung in den Bereichen Kosmetik-Inhaltsstoffe und Arzneimittel spezialisiert hat.
" alt="Vena Announces Proposed Private Placement and Provides Corporate Update
Datum: 22.09.2014 - 13:02 Uhr
Sprache: Deutsch
News-ID 337916
Anzahl Zeichen: 5348
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sirona Biochem Launches Anti-aging Preclinical Studies
"
steht unter der journalistisch-redaktionellen Verantwortung von
Sirona Biochem Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
